Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.
semaglutideorforglipron
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapieFeb 2024
GLP-1 Research Tracker
Every clinical trial and published study on semaglutide, tirzepatide, and next-generation GLP-1 medications — curated with plain-language summaries.
234 studies tracked·6 compounds covered·Updated Jul 2026
The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update.
retatrutide
Endocrinology and metabolism (Seoul, Korea)Feb 2024
Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.
orforglipron
Archives of endocrinology and metabolismJan 2024
Crowdsourcing-Based Knowledge Graph Construction for Drug Side Effects Using Large Language Models with an Application on Semaglutide.
semaglutide
AMIA ... Annual Symposium proceedings. AMIA SymposiumJan 2024
Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions.
semaglutidetirzepatideliraglutideretatrutide
Gastroenterology reportJan 2024
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
orforglipron
Metabolism: clinical and experimentalDec 2023
Phase 1
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
orforglipron
The New England journal of medicineSep 2023
Phase 1
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
orforglipron
Diabetes, obesity & metabolismSep 2023
Phase 1
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
orforglipron
Diabetes, obesity & metabolismSep 2023
Phase 2
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
retatrutide
Lancet (London, England)Aug 2023
Phase 2
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
retatrutide
The New England journal of medicineAug 2023
Phase 2
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
semaglutideorforglipron
Lancet (London, England)Aug 2023
Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
semaglutidetirzepatideretatrutide
Expert opinion on investigational drugsMay 2023
Retatrutide showing promise in obesity (and type 2 diabetes).
semaglutidetirzepatideretatrutide
Expert opinion on investigational drugsJan 2023
Get Weekly Research Updates
New clinical trials, study results, and plain-language summaries delivered to your inbox.
Free weekly newsletter · No spam, unsubscribe anytime